Mirum Pharmaceuticals Inc (MIRM)vsVertex Pharmaceuticals Inc (VRTX)
MIRM
Mirum Pharmaceuticals Inc
$100.65
+6.94%
HEALTHCARE · Cap: $6.46B
VRTX
Vertex Pharmaceuticals Inc
$496.07
+2.49%
HEALTHCARE · Cap: $121.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2110% more annual revenue ($12.59B vs $569.61M). VRTX leads profitability with a 35.0% profit margin vs -140.2%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
MIRM
Avoid30
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.8%
Fair Value
$187.59
Current Price
$100.65
$86.94 discount
Margin of Safety
+50.1%
Fair Value
$971.64
Current Price
$496.07
$475.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 43.3% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Trading at 25.3x book value
ROE of -329.4% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth. Revenue growth of 43.3% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : MIRM
The primary concerns for MIRM are EPS Growth, Debt/Equity, Price/Book.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MIRM profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.48 — expect wider price swings.
MIRM is growing revenue faster at 43.3% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 30/100), backed by strong 35.0% margins and 12.5% revenue growth. MIRM offers better value entry with a 46.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?